Introduction Hypersensitivity reactions from intravenous (IV) etoposide have been rarely
reported, with these being seen more commonly with etoposide than with etoposide …

Two bioactive natural products derivatives including hydroxycamptothecin (HCPT) and
etoposide (EPEG), which are one of the most common classes of first-line anticancer drugs …

Etoposide is an antineoplastic agent widely used for treatment of many pediatric cancers.
Etoposide has been associated with infusion‐related reactions. In this brief report, we …

Introduction A case series of hypersensitivity reactions (HSRs) during intravenous
administration of etoposide was observed following the introduction of in-line filters (ILFs) at …

PURPOSE Etoposide, a topoisomerase II inhibitor used clinically to treat cancer, has been
associated with severe anaphylactic infusion related adverse drug reactions (ADRs). In a …

Introduction Etoposide is a key component of many pediatric chemotherapy regimens for
both hematologic and solid tumors. It is well documented that patients receiving etoposide …

Aims: This study aims to define characteristics of hypersensitivity reactions with etoposide,
and outcomes of desensitizations in immediate-type hypersensitivity rections Methods: This …

Etoposide administration can be complicated by hypersensitivity reactions. Desensitization
may provide a strategy to prevent hypersensitivity recurrence. One challenge with …

Aims: This study aims to define characteristics of hypersensitivity reactions with etoposide,
and outcomes of desensitizations in immediate-type hypersensitivity rections Methods: This …

Methods: Retrospective study of pediatric patients treated with etoposide since June 2013
until September 2020. Symptoms of hypersensitivity, grade of hypersensitivity reaction …